Brian Powl
Corporate Officer/Principal at KURA ONCOLOGY, INC.
Net worth: 621 962 $ as of 2024-03-30
Profile
Brian T.
Powl is currently the Chief Commercial Officer at Kura Oncology, Inc. He previously worked as the Vice President-Global Commercial CAR T Lead at Celgene Corp., Senior VP-Commercial Development & Marketing at MEI Pharma, Inc., and Chief Commercial Officer at Fate Therapeutics, Inc. Powl received his undergraduate degree from the University of California San Diego and his MBA from The Wharton School of the University of Pennsylvania.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.02% | 2024-01-01 | 15,000 ( 0.02% ) | 319 950 $ | 2024-03-30 |
FATE THERAPEUTICS, INC.
0.04% | 2023-07-04 | 41,146 ( 0.04% ) | 302 012 $ | 2024-03-30 |
Brian Powl active positions
| Companies | Position | Start |
|---|---|---|
| KURA ONCOLOGY, INC. | Corporate Officer/Principal | 2023-08-13 |
Former positions of Brian Powl
| Companies | Position | End |
|---|---|---|
| CELGENE | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
| MEI PHARMA, INC. | Sales & Marketing | - |
Training of Brian Powl
| University of California San Diego | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| KURA ONCOLOGY, INC. | Health Technology |
| MEI PHARMA, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Stock Market
- Insiders
- Brian Powl
